Edgewise Historical Balance Sheet

EWTX Stock

USD 23.27 0.17 0.73%

Trend analysis of Edgewise Therapeutics balance sheet accounts such as Other Current Liabilities of 8.8 M or Total Current Liabilities of 13.4 M provides information on Edgewise Therapeutics' total assets, liabilities, and equity, which is the actual value of Edgewise Therapeutics to its prevalent stockholders. By breaking down trends over time using Edgewise Therapeutics balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.

Cash Flow Balance Sheet Income Statement

Covid

Financial Statement Analysis is much more than just reviewing and examining Edgewise Therapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Edgewise Therapeutics is a good buy for the upcoming year.

Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Edgewise Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

For more information on how to buy Edgewise Stock please use our How to Invest in Edgewise Therapeutics guide.

About Edgewise Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of Edgewise Therapeutics at a specified time, usually calculated after every quarter, six months, or one year. Edgewise Therapeutics Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Edgewise Therapeutics and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Edgewise currently owns. An asset can also be divided into two categories, current and non-current.

Edgewise Therapeutics Balance Sheet Chart

At this time, Edgewise Therapeutics' Net Tangible Assets are fairly stable compared to the past year. Other Current Assets is likely to rise to about 5.7 M in 2025, whereas Total Assets are likely to drop slightly above 299.7 M in 2025.

Total Assets Short Long Term Debt Total Other Current Liab Total Current Liabilities

Add Fundamental

Total Assets

Total assets refers to the total amount of Edgewise Therapeutics assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Edgewise Therapeutics books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Total Current Liabilities

Total Current Liabilities is an item on Edgewise Therapeutics balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Edgewise Therapeutics are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Most accounts from Edgewise Therapeutics' balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Edgewise Therapeutics current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Edgewise Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

For more information on how to buy Edgewise Stock please use our How to Invest in Edgewise Therapeutics guide.At this time, Edgewise Therapeutics' Net Tangible Assets are fairly stable compared to the past year. Other Current Assets is likely to rise to about 5.7 M in 2025, whereas Total Assets are likely to drop slightly above 299.7 M in 2025.

	2023	2024	2025 (projected)
Short and Long Term Debt Total	5.4M	4.7M	4.5M
Total Assets	340.0M	486.8M	299.7M

Short Long Term Debt Total Total Assets

Edgewise Therapeutics balance sheet Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Net Tangible Assets	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Cash And Short Term Investments	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Net Invested Capital	Property Plant And Equipment Gross	Total Current Assets	Net Working Capital	Property Plant Equipment	Non Currrent Assets Other	Other Assets	Deferred Long Term Liab
Total Assets		-0.44	0.98	0.99	0.98	0.95	0.89	-0.64	-0.88	0.98	0.57	0.93	1.0	0.79	-0.45	0.9	0.93	-0.24	0.98	0.86	1.0	1.0	0.89	0.28	-0.96	-0.96
Short Long Term Debt Total	-0.44		-0.46	-0.48	-0.6	-0.61	-0.5	0.52	0.48	-0.48	-0.21	-0.51	-0.44	-0.39	1.0	-0.56	-0.56	0.96	-0.6	-0.5	-0.44	-0.44	-0.52	-0.22	0.59	0.59
Other Current Liab	0.98	-0.46		0.99	0.97	0.93	0.92	-0.51	-0.92	0.93	0.41	0.91	0.98	0.88	-0.47	0.84	0.93	-0.26	0.97	0.9	0.98	0.98	0.9	0.12	-0.94	-0.93
Total Current Liabilities	0.99	-0.48	0.99		0.98	0.95	0.93	-0.59	-0.9	0.97	0.49	0.94	0.99	0.84	-0.49	0.88	0.94	-0.27	0.98	0.89	0.99	0.99	0.92	0.22	-0.96	-0.95
Total Stockholder Equity	0.98	-0.6	0.97	0.98		0.97	0.89	-0.69	-0.86	0.97	0.56	0.93	0.98	0.78	-0.61	0.92	0.93	-0.42	1.0	0.85	0.98	0.98	0.88	0.32	-0.96	-0.98
Net Tangible Assets	0.95	-0.61	0.93	0.95	0.97		0.87	-0.66	-0.91	0.95	0.52	0.92	0.95	0.73	-0.62	0.92	0.98	-0.4	0.97	0.9	0.95	0.95	0.93	0.26	-0.99	-0.96
Property Plant And Equipment Net	0.89	-0.5	0.92	0.93	0.89	0.87		-0.48	-0.85	0.87	0.36	0.96	0.88	0.77	-0.5	0.87	0.86	-0.31	0.89	0.92	0.88	0.88	0.94	0.12	-0.92	-0.85
Net Debt	-0.64	0.52	-0.51	-0.59	-0.69	-0.66	-0.48		0.3	-0.76	-0.95	-0.68	-0.65	-0.11	0.53	-0.82	-0.49	0.45	-0.69	-0.31	-0.64	-0.65	-0.45	-0.88	0.65	0.77
Retained Earnings	-0.88	0.48	-0.92	-0.9	-0.86	-0.91	-0.85	0.3		-0.82	-0.16	-0.81	-0.88	-0.9	0.48	-0.72	-0.98	0.24	-0.86	-0.97	-0.88	-0.88	-0.95	0.12	0.91	0.8
Accounts Payable	0.98	-0.48	0.93	0.97	0.97	0.95	0.87	-0.76	-0.82		0.68	0.95	0.98	0.69	-0.49	0.94	0.9	-0.29	0.97	0.81	0.98	0.98	0.88	0.45	-0.96	-0.96
Cash	0.57	-0.21	0.41	0.49	0.56	0.52	0.36	-0.95	-0.16	0.68		0.59	0.57	-0.02	-0.23	0.73	0.35	-0.16	0.56	0.17	0.56	0.57	0.32	0.92	-0.52	-0.65
Non Current Assets Total	0.93	-0.51	0.91	0.94	0.93	0.92	0.96	-0.68	-0.81	0.95	0.59		0.92	0.66	-0.51	0.96	0.87	-0.32	0.93	0.87	0.92	0.92	0.93	0.36	-0.95	-0.92
Cash And Short Term Investments	1.0	-0.44	0.98	0.99	0.98	0.95	0.88	-0.65	-0.88	0.98	0.57	0.92		0.79	-0.45	0.89	0.93	-0.23	0.98	0.85	1.0	1.0	0.88	0.29	-0.95	-0.96
Common Stock Shares Outstanding	0.79	-0.39	0.88	0.84	0.78	0.73	0.77	-0.11	-0.9	0.69	-0.02	0.66	0.79		-0.4	0.51	0.82	-0.21	0.78	0.84	0.79	0.78	0.8	-0.25	-0.73	-0.67
Non Current Liabilities Total	-0.45	1.0	-0.47	-0.49	-0.61	-0.62	-0.5	0.53	0.48	-0.49	-0.23	-0.51	-0.45	-0.4		-0.57	-0.57	0.96	-0.61	-0.5	-0.45	-0.45	-0.52	-0.23	0.59	0.61
Other Current Assets	0.9	-0.56	0.84	0.88	0.92	0.92	0.87	-0.82	-0.72	0.94	0.73	0.96	0.89	0.51	-0.57		0.83	-0.39	0.92	0.77	0.89	0.89	0.84	0.51	-0.94	-0.95
Other Stockholder Equity	0.93	-0.56	0.93	0.94	0.93	0.98	0.86	-0.49	-0.98	0.9	0.35	0.87	0.93	0.82	-0.57	0.83		-0.33	0.93	0.95	0.93	0.93	0.95	0.08	-0.97	-0.89
Total Liab	-0.24	0.96	-0.26	-0.27	-0.42	-0.4	-0.31	0.45	0.24	-0.29	-0.16	-0.32	-0.23	-0.21	0.96	-0.39	-0.33		-0.42	-0.27	-0.23	-0.23	-0.29	-0.24	0.37	0.42
Net Invested Capital	0.98	-0.6	0.97	0.98	1.0	0.97	0.89	-0.69	-0.86	0.97	0.56	0.93	0.98	0.78	-0.61	0.92	0.93	-0.42		0.85	0.98	0.98	0.88	0.32	-0.96	-0.98
Property Plant And Equipment Gross	0.86	-0.5	0.9	0.89	0.85	0.9	0.92	-0.31	-0.97	0.81	0.17	0.87	0.85	0.84	-0.5	0.77	0.95	-0.27	0.85		0.85	0.85	0.98	-0.1	-0.92	-0.8
Total Current Assets	1.0	-0.44	0.98	0.99	0.98	0.95	0.88	-0.64	-0.88	0.98	0.56	0.92	1.0	0.79	-0.45	0.89	0.93	-0.23	0.98	0.85		1.0	0.88	0.28	-0.96	-0.96
Net Working Capital	1.0	-0.44	0.98	0.99	0.98	0.95	0.88	-0.65	-0.88	0.98	0.57	0.92	1.0	0.78	-0.45	0.89	0.93	-0.23	0.98	0.85	1.0		0.88	0.29	-0.95	-0.96
Property Plant Equipment	0.89	-0.52	0.9	0.92	0.88	0.93	0.94	-0.45	-0.95	0.88	0.32	0.93	0.88	0.8	-0.52	0.84	0.95	-0.29	0.88	0.98	0.88	0.88		0.08	-0.95	-0.83
Non Currrent Assets Other	0.28	-0.22	0.12	0.22	0.32	0.26	0.12	-0.88	0.12	0.45	0.92	0.36	0.29	-0.25	-0.23	0.51	0.08	-0.24	0.32	-0.1	0.28	0.29	0.08		-0.26	-0.4
Other Assets	-0.96	0.59	-0.94	-0.96	-0.96	-0.99	-0.92	0.65	0.91	-0.96	-0.52	-0.95	-0.95	-0.73	0.59	-0.94	-0.97	0.37	-0.96	-0.92	-0.96	-0.95	-0.95	-0.26		0.96
Deferred Long Term Liab	-0.96	0.59	-0.93	-0.95	-0.98	-0.96	-0.85	0.77	0.8	-0.96	-0.65	-0.92	-0.96	-0.67	0.61	-0.95	-0.89	0.42	-0.98	-0.8	-0.96	-0.96	-0.83	-0.4	0.96

Click cells to compare fundamentals

Edgewise Therapeutics Account Relationship Matchups

Edgewise Therapeutics balance sheet Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Total Assets	131.1M	285.2M	367.1M	340.0M	486.8M	299.7M
Other Current Liab	2.8M	6.7M	9.3M	11.8M	17.3M	8.8M
Total Current Liabilities	4.3M	10.5M	16.6M	16.8M	23.9M	13.4M
Total Stockholder Equity	(33.4M)	274.4M	346.7M	318.8M	459.2M	247.3M
Property Plant And Equipment Net	516K	912K	9.9M	12.7M	11.1M	6.5M
Net Debt	55.3M	(280.8M)	(347.5M)	(80.7M)	(36.9M)	(38.8M)
Retained Earnings	(34.1M)	(77.0M)	(144.6M)	(244.8M)	(378.6M)	(359.6M)
Accounts Payable	1.6M	3.8M	6.1M	4.0M	5.6M	4.0M
Cash	104.9M	280.8M	351.9M	86.1M	41.7M	39.6M
Non Current Assets Total	1.5M	4.4M	15.2M	13.0M	11.3M	8.4M
Cash And Short Term Investments	129.1M	280.8M	351.9M	318.4M	470.2M	288.6M
Short Term Investments	24.2M	265.2M	330.0M	232.3M	428.5M	234.7M
Liabilities And Stockholders Equity	131.1M	285.2M	367.1M	340.0M	486.8M	299.7M
Non Current Liabilities Total	160.2M	329K	3.8M	4.4M	3.7M	3.6M
Other Current Assets	551K	6.0M	10.1M	8.6M	5.3M	5.7M
Other Stockholder Equity	727K	351.9M	492.7M	563.5M	837.4M	879.2M
Total Liab	164.6M	10.9M	20.4M	21.2M	27.6M	38.1M
Net Invested Capital	(33.4M)	274.4M	346.7M	318.8M	459.2M	247.3M
Property Plant And Equipment Gross	516K	912K	8.5M	15.3M	15.8M	16.5M
Total Current Assets	129.6M	280.8M	351.9M	327.0M	475.5M	291.3M
Accumulated Other Comprehensive Income	(430K)	(514K)	(1.4M)	99K	420K	441K
Net Working Capital	125.3M	273.3M	340.4M	310.2M	451.6M	279.4M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

ZLAB	Zai Lab
ASLE	AerSale Corp
ATS	AT S Austria

Additional Tools for Edgewise Stock Analysis

When running Edgewise Therapeutics' price analysis, check to measure Edgewise Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Edgewise Therapeutics is operating at the current time. Most of Edgewise Therapeutics' value examination focuses on studying past and present price action to predict the probability of Edgewise Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Edgewise Therapeutics' price. Additionally, you may evaluate how the addition of Edgewise Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Edgewise Historical Balance Sheet

About Edgewise Balance Sheet Analysis

Edgewise Therapeutics Balance Sheet Chart

Total Assets

Total Current Liabilities

Edgewise Therapeutics balance sheet Correlations

Edgewise Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Edgewise Therapeutics balance sheet Accounts

Also Currently Popular

Additional Tools for Edgewise Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cash And Short Term Investments	+ 1.0	Total Assets
Total Current Assets	+ 1.0	Total Assets
Net Working Capital	+ 1.0	Total Assets
Non Current Liabilities Total	+ 1.0	Short Long Term Debt Total
Net Invested Capital	+ 1.0	Total Stockholder Equity
Total Current Assets	+ 1.0	Cash And Short Term Investments

Other Assets	- 0.99	Net Tangible Assets
Deferred Long Term Liab	- 0.98	Net Invested Capital
Other Stockholder Equity	- 0.98	Retained Earnings
Deferred Long Term Liab	- 0.98	Total Stockholder Equity
Other Assets	- 0.97	Other Stockholder Equity
Property Plant And Equipment Gross	- 0.97	Retained Earnings